Allergan forecast 2019 revenue below analysts’ estimates, as it faces impending competition for its second-most important medicine, the eye drug Restasis. Photograph: Thomas White/Reuters

Irish-headquartered botox maker Allergan is no longer looking at selling its women’s health business, chief executive Brent Saunders said on Tuesday. (...)

IPHA president GSK’s Aidan Lynch (centre); IPHA vice-president Paul Reid (Pfizer); and Bayer’s Itziar Canamasas with the Manifesto for Better Health ahead of the IPHA annual conference on November 8th. Photograph: Justin Mac Innes

Big Pharma in Ireland has an image problem. At least that’s how it sees it. “I think we are not seen as a trusted partner,” says Aidan Lynch, presid(...)

Allergan chief executive Brent Saunders: “We are an Irish company. It’s part of who we are. Ireland is in Allergan’s DNA.” Photograph: Nick Bradshaw

Never has a toxin been so good for a town, a country or a company. In fact, Botox has been such a profit driver for Allergan, the multinational headq(...)

Analysts see Allergan’s acquisition of  Vitae Pharmaceuticals as a risky, research-focused deal for drugs that are still in development and face heavy competition. Photograph: Thomas White/Reuters

Allergan, the maker of wrinkle smoothener Botox that employs about 900 people in Ireland, said it would spend $639 million (€567 million) to acquire V(...)

Allergan chief executive Brent Saunders gives an interview on the floor of the New York Stock Exchange as Allergan and Pfizer announce the end of their plan to merge. Photograph:  reuters/Brendan McDermid

Pfizer and Allergan have terminated their $160 billion merger in an abrupt end to the largest healthcare deal yet after the US government cracked down(...)

Irish-based drug company Allergan reported better-than-expected quarterly revenue, helped by strong performance in its US brands segment, and said it (...)

Ian Read, chief executive of Pfizer, and Brent Saunders, chief executive of Allergan. Photograph: Michael Nagle/Bloomberg

Drug giant Pfizer has announced a $160 billion (€150.5bn) takeover of Dublin-headquartered Allergan in a deal that will make Ireland home to the worl(...)

Pfizer is in negotiations with Dublin-based Allergan about buying the group in what would be the biggest ever “tax inversion” — allowing the company to report much lower tax costs by moving its domicile to Ireland. (Photograph: Scott Eisen/Bloomberg)

The chief executive of Allergan, in talks about selling itself to Pfizer to form the world’s largest drugmaker, has cautioned that any attempt by the(...)

To pull off the merger, Pfizer simply needs to ensure it has control of no more than 60 per cent of the merged company. Photograph: Michael Mac Sweeney.

Amid the clamour over Pfizer’s approach to Allergan about a possible merger, one thing has escaped attention. It will come as a relief to the US drug (...)